Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Birth with Synthetic Oxytocin and Risk of Childhood Emotional Disorders: A Danish Population-based Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Common mental disorders among young refugees in Sweden: The role of education and duration of residency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hypomania/Mania by DSM-5 definition based on daily smartphone-based patient-reported assessments

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To investigate the efficacy of adjunctive N-acetylcysteine (NAC) for the treatment of acute bipolar depression.

METHOD: A randomized, double-blind, multicentre, placebo-controlled trial including adult subjects diagnosed with bipolar disorder, currently experiencing a depressive episode. Participants were treated with 3 g/day NAC or placebo as an adjunctive to standard treatment for 20 weeks, followed by a 4-week washout where the blinding was maintained. The primary outcome was the mean change in the Montgomery Asberg Depression Rating Scale (MADRS) score over the 20-week treatment phase. Linear Mixed Effects Repeated Measures (LMERM) was used for analysing the primary outcome.

RESULTS: A total of 80 subjects were included. The mean MADRS score at baseline was 30.1 and 28.8 in participants randomized to NAC and placebo, respectively. Regarding the primary outcome measure, the between-group difference (NAC vs. placebo) was 0.5, which was statistically non-significant (95% CI: -7.0-5.9;p = 0.88). All findings regarding secondary outcomes were statistically or clinically insignificant.

LIMITATIONS: The study had a placebo response rate of 55.6% - high placebo response rates are associated with failure to separate from placebo.

CONCLUSIONS: Based on our primary outcome measure, we could not confirm previous studies showing a therapeutic effect of adjunctive NAC treatment on acute bipolar depression. Further studies with larger samples are needed to elucidate if specific subgroups could benefit from adjunctive NAC treatment.

TidsskriftJournal of Affective Disorders
Sider (fra-til)1043-1051
Antal sider9
StatusUdgivet - 15 feb. 2019

ID: 56643149